Skip to main content
Header logo
  • About Moberg Open link menu
    About Moberg
    • CEO Comments
    • Business Model
    • Board and Leadership
  • MOB-015
  • Sustainability
  • Investors Open link menu
    Investors
    • Results and Presentations
    • The share Open link menu
      The share
      • Major shareholders
      • Insider Trading
      • Financial Data
    • Analysts
    • Calender
    • Corporate governance Open link menu
      Corporate governance
      • Board of directors
      • Management
      • General shareholders meetings
      • Nomination committee
      • Auditors
      • Remuneration
      • Share-based incentive program
      • Articles of Association
    • Press releases
    • Prospectus
  • Media Open link menu
    Media
    • Image Archive
    • Press Releases
  • Contact
    • EN Current language English, click to switch language
    • SV Switch to Swedish
  • Please fill out this field
Close
Please fill out this field
Press Releases
Breadcrumbs
  • Home
  • Media
  • Press Releases

Press Releases

Press Releases Regulatory Press Releases
More
Press Releases Data
2025-05-13 08:00
Moberg Pharma interim report January - March 2025
Read more
2025-04-22 08:00
Notice of Annual General Meeting in Moberg Pharma AB (publ)
Read more
2025-04-11 08:00
Moberg Pharma's Annual report for 2024
Read more
2025-02-11 08:00
Moberg Pharma Year-end report 2024
Read more
2025-02-03 08:00
Terclara (MOB-015) is now being launched in Norway
Read more
2024-12-18 08:00
New terbinafine supplier secured
Read more

Pagination

  • First page
  • Previous page
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page
  • Last page
Press Releases Data
2025-04-22 08:00
Notice of Annual General Meeting in Moberg Pharma AB (publ)
Read more
2025-04-11 08:00
Moberg Pharma's Annual report for 2024
Read more
2025-02-11 08:00
Moberg Pharma Year-end report 2024
Read more
2024-12-18 08:00
New terbinafine supplier secured
Read more
2024-12-10 20:30
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
Read more
2024-11-12 08:00
Moberg Pharma's Interim report January - September 2024
Read more

Pagination

  • First page
  • Previous page
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page
  • Last page
What we do

Moberg Pharma AB
Telephone: 08-522 307 00
Email: [email protected]

Mailing Address: 
Gustavslundsvägen 42, 167 51 Bromma
Visiting Address: 
Gustavslundsvägen 50, 167 51 Bromma

Sign up to receive our press releases and reports.

Sign up

Home
Moberg Pharma´s Interim report January - September 2024

Footer

  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Cookies
  • Copyright
  • Cookie settings
  • © Moberg Pharma AB (publ) 2025